XML 27 R19.htm IDEA: XBRL DOCUMENT v3.26.3
Stock-based Compensation
9 Months Ended
Sep. 30, 2026
Share-Based Payment Arrangement [Abstract]  
Stock-based Compensation

9. Stock-based Compensation

Stock‑based compensation expense recognized was as follows (in thousands):

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Research and development

 

$

1,011

 

 

$

574

 

 

$

2,154

 

 

$

1,737

 

General and administrative

 

 

2,578

 

 

 

836

 

 

 

5,278

 

 

 

2,907

 

Total stock-based compensation
   expense

 

$

3,589

 

 

$

1,410

 

 

$

7,432

 

 

$

4,644

 

 

Valuation Assumptions

The fair value of stock options was determined using the Black-Scholes option-pricing model and the assumptions below. Each of these inputs is subjective and generally requires significant judgment.

•
Fair Value of Common Stock—The fair value of each share of common stock is based on the closing price of the Company’s common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Capital Market.
•
Risk-Free Interest Rate—The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option.
•
Expected Volatility—Because the Company was previously privately held and did not have any trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded life sciences companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on the similar size, stage in life cycle or area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.
•
Expected Term—The expected term represents the period that the stock-based awards are expected to be outstanding and is determined using the simplified method (based on the midpoint between the vesting date and the end of the contractual term) as the Company has limited history of relevant stock option exercise activity.
•
Expected Dividend Yield—The Company has never paid dividends on its common stock and has no plans to pay dividends going forward. Therefore, it used an expected dividend yield of zero.

The fair value of each stock option was estimated using the Black‑Scholes option‑pricing model with the following weighted-average assumptions:

 

 

 

Nine Months Ended September 30,

 

 

 

2026

 

 

2025

 

Risk-free interest rate

 

 

4.03

%

 

 

3.98

%

Expected volatility

 

 

105.85

%

 

 

100.54

%

Expected term (in years)

 

 

5.98

 

 

 

5.97

 

Expected dividend yield

 

 

—

 

 

 

—

 

 

The grant date fair value of RSUs is based upon the fair market value of the Company’s common stock based on its closing price as reported on the date of grant on the Nasdaq Capital Market.

The fair value of options granted during the nine months ended September 30, 2026 and 2025 was $38.0 million and $0.4 million, respectively. The fair value of RSUs granted during the nine months ended September 30, 2026 and 2025 was $1.6 million and $0.2 million, respectively.

Stock Option Activity

Changes in shares available for grant under the 2026 Plan, the 2020 Plan, and the 2024 Inducement Plan during the nine months ended September 30, 2026 were as follows:

 

 

 

Shares
Available
for Grant

 

Shares available for grant at December 31, 2025

 

 

98,723

 

2020 Plan reserve increase on January 1, 2026

 

 

323,000

 

Options and restricted stock units granted

 

 

(5,098,454

)

Options and restricted stock units forfeited,
   cancelled, or expired

 

 

47,513

 

Termination of future use of 2020 Plan

 

 

(355,345

)

Shares reserved for issuance under 2026 Plan

 

 

5,700,000

 

Shares available for grant at September 30, 2026

 

 

715,437

 

 

A summary of stock option activity under the 2026 Plan, the 2020 Plan, and the 2024 Inducement Plan for the nine months ended September 30, 2026 is as follows:

 

 

 

Shares

 

 

Weighted-
Average
Exercise
price
per Share

 

 

Weighted-
Average
Remaining
Contractual
Term
(in years)

 

 

Aggregate
Intrinsic
Value
(in thousands)

 

Balance at December 31, 2025

 

 

1,204,829

 

 

$

37.44

 

 

8.14

 

 

$

2,030

 

Granted

 

 

4,933,454

 

 

 

9.30

 

 

 

—

 

 

 

—

 

Exercised

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Forfeited/expired

 

 

(47,513

)

 

 

27.90

 

 

 

—

 

 

 

—

 

Balance at September 30, 2026

 

 

6,090,770

 

 

$

14.72

 

 

 

9.14

 

 

$

5

 

Expected to vest

 

 

5,061,217

 

 

$

9.20

 

 

 

9.47

 

 

 

—

 

Options exercisable

 

 

1,029,553

 

 

$

41.89

 

 

 

7.51

 

 

$

5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The total fair value of options granted that vested during the nine months ended September 30, 2026 and 2025 was $4.3 million and $5.9 million, respectively.

The aggregate intrinsic value in the table above is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the Company’s common stock underlying all options that were in-the-money at September 30, 2026. There were no options exercised during the nine months ended September 30, 2026 and 2025. As of September 30, 2026, there was $36.1 million of total unrecognized compensation cost related to non-vested stock options. The Company expects to recognize this cost over a remaining weighted-average period of 3.2 years. The Company utilizes newly issued shares to satisfy option exercises.

Stock options outstanding and exercisable under the 2026 Plan, the 2020 Plan, and the 2024 Inducement Plan consisted of the following at September 30, 2026.

 

 

 

 

 

Exercise Price ($)

 

Options
Outstanding

 

 

Options
Exercisable

 

3.13 to 7.14

 

 

628,261

 

 

 

138,363

 

7.47 to 13.50

 

 

4,849,621

 

 

 

363,375

 

20.40 to 41.10

 

 

406,844

 

 

 

321,771

 

89.30 to 294.10

 

 

206,044

 

 

 

206,044

 

Total

 

 

6,090,770

 

 

 

1,029,553

 

 

Restricted Stock Unit Activity

A summary of restricted stock unit ("RSU") activity under the 2026 Plan and the 2020 Plan for the nine months ended September 30, 2026 is as follows:

 

 

 

Share
Equivalent

 

 

Weighted-
Average
Grant Date
Fair Value

 

Non-vested at December 31, 2025

 

 

57,601

 

 

$

3.76

 

Granted

 

 

165,000

 

 

 

9.54

 

Cancelled

 

 

—

 

 

 

—

 

Vested

 

 

(57,601

)

 

 

3.76

 

Non-vested at September 30, 2026

 

 

165,000

 

 

$

9.54

 

 

As of September 30, 2026, there was $0.6 million of total unrecognized compensation costs related to non-vested RSUs. The Company expects to recognize this cost over a remaining weighted-average period of 0.16 years.